Longevity
Mitochondrial Derived Peptide
A mitochondrial-derived peptide studied for metabolic regulation and insulin sensitivity.
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA. Research interest covers metabolic regulation, insulin sensitivity, and exercise mimetic effects. Most data is preclinical with a small body of early human work.
Where to buy
Some links on this page are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.
Best $/mg
Evidence level
Early human studies
A 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene. Acts as an exercise-mimetic by activating AMPK; early human data is promising but limited.
Mechanism
Activates AMPK and modulates mitochondrial energy metabolism.
Researched benefits
Mitochondrial biogenesis
Activates AMPK, which upregulates PGC-1α and the downstream mitochondrial biogenesis program. Mouse skeletal muscle and liver show measurable increases in mitochondrial density.
Insulin sensitization
Improves glucose disposal in diet-induced obese and aged mice; a single small human study (n=22) showed improved oral glucose tolerance after 16 days.
Exercise-mimetic effects
Increases endurance and lean mass retention in rodent models, even in sedentary animals. Mechanism overlaps with metformin via AMPK.
Bone density (preclinical)
Mouse osteoporosis models show preserved trabecular bone after MOTS-c administration.
Risks & cautions
Limited long-term human data
Only a handful of small human studies exist. Most safety inferences are extrapolated from short rodent trials. Endogenous MOTS-c suggests low baseline toxicity, but exogenous supraphysiologic dosing is not characterized.
Possible hypoglycemia
AMPK activation can lower fasting glucose. Caution when stacked with metformin, GLP-1 agonists, or insulin.
Unknown effects on cancer pathways
AMPK is upstream of mTOR. Both tumor-suppressive and tumor-protective effects have been reported in different cancer models. Avoid with active malignancy until more data exists.
Injection-site reactions
Standard subcutaneous risks: erythema, transient bruising, lipohypertrophy with repeated use of the same site.
Dosing
5–10 mg subcutaneously, 2–3× per week, in 4–8 week cycles.
Vial sizes
10mg
Half-life
~30 minutes
Route
subcutaneous
Reconstitute with bacteriostatic water. Half-life is short (~30 min plasma) so weekly cumulative dose matters more than per-injection frequency.
Contraindications
In depth
MOTS-c (Mitochondrial Open Reading frame of the Twelve S rRNA-c) is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene — one of a small family of mitochondrial-derived peptides discovered in the last fifteen years. It is a signaling molecule, not a structural protein: it shuttles from mitochondria to the nucleus under metabolic stress and modulates nuclear gene expression.
Endogenous plasma MOTS-c declines with age. Acute exercise transiently raises it. These observations are the basis for the "exercise-mimetic" framing.
The dominant pathway is AMPK activation. Under metabolic stress (fasting, exercise, caloric restriction) MOTS-c translocates to the nucleus and:
The mitochondria-to-nucleus communication is what makes MOTS-c structurally interesting — it is part of a retrograde signaling system that classical biology assumed didn't exist at the peptide level.
Human data is limited:
No phase II or III trials exist. There is no approved indication.
Substantial. Rodent studies show consistent improvements in:
These effects are reproducible across labs and dose ranges. Translation to humans at equivalent doses is the open question.
Frequently stacked with:
Caution stacking with anything that lowers blood glucose (metformin, semaglutide, tirzepatide) — the additive AMPK effect can produce unwanted hypoglycemia.
References
